# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060025
Filing Date
2024-05-15
Accepted
2024-05-15 07:00:37
Documents
63
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | eldn-20240331.htm iXBRL | 10-Q | 1429138
2 | EX-31.1 | eldn-ex31_1.htm | EX-31.1 | 14299
3 | EX-31.2 | eldn-ex31_2.htm | EX-31.2 | 14557
4 | EX-32.1 | eldn-ex32_1.htm | EX-32.1 | 9090
5 | EX-32.2 | eldn-ex32_2.htm | EX-32.2 | 9152
| Complete submission text file | 0000950170-24-060025.txt |  | 6325713

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | eldn-20240331.xsd | EX-101.SCH | 966854
66 | EXTRACTED XBRL INSTANCE DOCUMENT | eldn-20240331_htm.xml | XML | 989554

Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36620 | Film No.: 24947091
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)